YCYing Cao

Ying Cao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ying Cao has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Financial Toxicity Among Long-Term Prostate Cancer Survivors—Results From a Population-Based Cohort

    by Rahul D. Mali, Katelyn Kane, Ying Cao, Aaron J. Katz, Deborah S. Usinger, Ronald C. Chen, Xinglei Shen

  • Open Access

    Shared metabolomic signatures for prognostic precision across brain injuries

    by Santtu Hellström, Antti Sajanti, Aditya Jhaveri, Ying Cao, Fredrika Koskimäki, Johannes Falter, Janek Frantzén, Seán B. Lyne, Tomi Rantamäki, Riikka Takala, et al.

  • Open Access

    Logistic Model in Clinical and Health Research—the Elephant and Blind Men

    by Ying Cao, Aaron J. Katz, Xinglei Shen, Ryan T. Morse, Christopher E. Lominska, Ronald C. Chen

    Logistic models are everywhere in scientific research, including clinical and health research. However, there is no practical report on research results that will utilize many available statistical tools but mostly 1 or 2 only, for a logistic model. We introduce 6 powerful statistical tools, forest plot, AUC curve, nomogram, and decision curve analysis, as well as bootstrapping sampling and cross validation, by applying head and neck cancer data to a logistic model. We hope that these tools will make the logistic model, and accordingly our research, more comprehensive and clinically more applicable. In the 6 parts of the article, we introduce each of the 6 statistical tools (methods) with relevant figures and interpretations on key statistical concepts to show how we can improve our understanding on the logistic model and the clinical prospects behind the data. The statistical tools we present in the current special communication for reporting research or clinical trials in a logistic model, if popularized among researchers and clinicians, will make a research conclusion more comprehensive, valid and clinically applicable to other cases.

  • Open Access

    Diagnostic and prognostic performance of urine ubiquitin carboxy-terminal hydrolase L1 across multiple acute brain injury types – A longitudinal prospective cohort study

    by Santtu Hellström, Antti Sajanti, Aditya Jhaveri, Abhinav Srinath, Carolyn Bennett, Ying Cao, Fredrika Koskimäki, Johannes Falter, Janek Frantzén, Seán B. Lyne, et al.


  • Open Access

    Incidence, surgical eligibility and outcome of spontaneous intracerebral haemorrhage in Southwest Finland – A retrospective study

    by Sami Lehto, Antti Sajanti, Santtu Hellström, Fredrika Koskimäki, Abhinav Srinath, Carolyn Bennett, Julián Carrión-Penagos, Ying Cao, Miro Jänkälä, Romuald Girard, et al.


  • Differences in Rural Versus Urban Patients With Prostate Cancer in Diagnosis and Treatment: An Analysis of a Population-Based Cohort

    by Xinglei Shen, Katelyn Kane, Aaron J. Katz, Deborah Usinger, Ying Cao, Ronald C. Chen

    PURPOSE: Patients living in rural communities have greater barriers to cancer care and poorer outcomes. We hypothesized that rural patients with prostate cancer have less access and receive different treatments compared with urban patients. METHODS: We used a population-based prospective cohort, the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study, to compare differences in prostate cancer diagnosis, access to care, and treatment in patients by geographic residence. The 2013 rural-urban continuum code (RUCC) was used to determine urban (RUCC 1-3) versus rural (RUCC 4-9) location of residence. RESULTS: Patients with rural residence comprised 25% of the cohort (364 of 1,444); they were less likely to be White race and had lower income and educational attainment. Rural patients were more likely to have <12 cores on biopsy (47.1% v 35.7%; P < .001) and less likely (40.8% v 47.6%; P = .04) to receive multidisciplinary consultation. We observed significant differences in treatment between urban and rural patients, including rural patients receiving less active surveillance or observation (22.6% v 28.7%), especially in low-risk cancer (33.2% v 40.7%). On multivariable analysis that adjusted for patient and diagnostic factors, rural residence was associated with less use of active surveillance or observation over radical treatment (ie, surgery or radiation therapy; odds ratio, 0.49 v urban; P < .001) in patients with low-risk cancer. CONCLUSION: Patients with prostate cancer who live in rural versus urban areas experience several differences in care that are likely clinically meaningful, including fewer cores in the diagnostic biopsy, less utilization of multidisciplinary consultation, less use of active surveillance, or observation for low-risk disease. Future studies are needed to assess the efficacy of interventions in mitigating these disparities.


  • Top Cited Papers
    Open Access

    Why is a small sample size not enough?

    by Ying Cao, Ronald C Chen, Aaron J Katz

    Clinical studies are often limited by resources available, which results in constraints on sample size. We use simulated data to illustrate study implications when the sample size is too small. Using 2 theoretical populations each with N = 1000, we randomly sample 10 from each population and conduct a statistical comparison, to help make a conclusion about whether the 2 populations are different. This exercise is repeated for a total of 4 studies: 2 concluded that the 2 populations are statistically significantly different, while 2 showed no statistically significant difference. Our simulated examples demonstrate that sample sizes play important roles in clinical research. The results and conclusions, in terms of estimates of means, medians, Pearson correlations, chi-square test, and P values, are unreliable with small samples.


  • Open Access

    Brain Plasticity Modulator p75 Neurotrophin Receptor in Human Urine after Different Acute Brain Injuries—A Prospective Cohort Study

    by Santtu Hellström, Antti Sajanti, Abhinav Srinath, Carolyn Bennett, Romuald Girard, Ying Cao, Janek Frantzén, Fredrika Koskimäki, Johannes Falter, Seán B. Lyne, et al.

    Acute brain injuries (ABIs) pose a substantial global burden, demanding effective prognostic indicators for outcomes. This study explores the potential of urinary p75 neurotrophin receptor (p75NTR) concentration as a prognostic biomarker, particularly in relation to unfavorable outcomes. The study involved 46 ABI patients, comprising sub-cohorts of aneurysmal subarachnoid hemorrhage, ischemic stroke, and traumatic brain injury. Furthermore, we had four healthy controls. Samples were systematically collected from patients treated at the University Hospital of Turku between 2017 and 2019, at early (1.50 ± 0.70 days) and late (9.17 ± 3.40 days) post-admission time points. Urinary p75NTR levels, measured by ELISA and normalized to creatinine, were compared against patients’ outcomes using the modified Rankin Scale (mRS). Early urine samples showed no significant p75NTR concentration difference between favorable and unfavorable mRS groups. In contrast, late samples exhibited a statistically significant increase in p75NTR concentrations in the unfavorable group (p = 0.033), demonstrating good prognostic accuracy (AUC = 70.9%, 95% CI = 53–89%, p = 0.03). Assessment of p75NTR concentration changes over time revealed no significant variation in the favorable group (p = 0.992) but a significant increase in the unfavorable group (p = 0.009). Moreover, p75NTR concentration was significantly higher in ABI patients (mean ± SD 40.49 ± 28.83–65.85 ± 35.04 ng/mg) compared to healthy controls (mean ± SD 0.54 ± 0.44 ng/mg), irrespective of sampling time or outcome (p < 0.0001). In conclusion, late urinary p75NTR concentrations emerged as a potential prognostic biomarker for ABIs, showing increased levels associated with unfavorable outcomes regardless of the specific type of brain injury. While early samples exhibited no significant differences, the observed late increases emphasize the time-dependent nature of this potential biomarker. Further validation in larger patient cohorts is crucial, highlighting the need for additional research to establish p75NTR as a reliable prognostic biomarker across various ABIs. Additionally, its potential role as a diagnostic biomarker warrants exploration.


  • Open Access

    Outcome and survival of surgically treated acute subdural hematomas and postcraniotomy hematomas – A retrospective cohort study

    by Iiro Heino, Antti Sajanti, Seán B. Lyne, Janek Frantzén, Romuald Girard, Ying Cao, Joel F. Ritala, Ari J. Katila, Riikka S.K. Takala, Jussi P. Posti, et al.


  • Open Access

    Sarcopenia and Treatment Toxicity in Older Adults Undergoing Chemoradiation for Head and Neck Cancer: Identifying Factors to Predict Frailty

    by Ryan T. Morse, Rohit G. Ganju, Gregory N. Gan, Ying Cao, Prakash Neupane, Kiran Kakarala, Yelizaveta Shnayder, Christopher E. Lominska

    This study was performed to identify treatment related toxicities in older adults undergoing concurrent chemoradiotherapy for head and neck cancer and nutritional and skeletal muscle measures that might identify frailty. Imaging analysis was done with the following skeletal muscle measurements: skeletal muscle index (SMI), skeletal muscle density (SMD), and skeletal muscle gauge (SMG). Patients were dichotomized by age into younger (p < 0.01), as were low SMD (57.8% vs. 37.3%, p = 0.012) and low SMG (76.1% vs. 44.2%, p < 0.01), despite having similar BMIs (27.3 kg/m2 versus 27.7 kg/m2, p = 0.71). Older patients were significantly more likely to experience chemotherapy toxicity than younger patients (54.9% versus 32.3%, p < 0.01). On multivariate analysis age (p < 0.01), current smoking status (p < 0.01), and low SMI (p < 0.01) remained as significant predictors for missed chemotherapy cycles or discontinuation. Older patients were more likely to require ≥5-day radiation breaks than younger patients (27.5% versus 8.6%, p < 0.01). On multivariate analysis, age (p < 0.01), low albumin status (p = 0.03), and low SMI (p = 0.04) were identified as predictors of prolonged radiation treatment breaks. Based on the results of our study, sarcopenia may be used as an additional marker for frailty alongside traditional performance status scales.